X
(All Fields are required)
Issue Brief

Letter From Pew and Medtronic to HHS Regarding the Physician Payments Sunshine Act


  • Nov 29, 2012

November  16,2012

Marilyn  B. Tavenner
Acting  Administrator, Centers for Medicare & Medicaid Services
U.S. Department  of HeaLth and Human Services
200 Independence  Avenue, S.W. Washington, D.C. 20201

Dear Ms Tavenner:

We are writing to urge you to fully implement Section ll28G of the Social Security Act, the Physician Payments Sunshine  Provision, which was added as Section 6002 of the Patient Protection and Affordable Care Act (PPACA).

This provision requires that manufacturers of drugs, devices, biologics or medical supplies, or their subsidiaries that sell these products in the United States, report to Health and Human Services (HHS) certain payments made to physicians and teaching hospitals. It reflects the recommendation by major medical, consumer and industry groups, as well as MedPAC and the Institute of Medicine, that Congress pass federal legislation to bring transparency to the financial relationships  between pharmaceutical and medical device companies, and health professionals and teaching hospitals.

This federal transparency provision has support from diverse stakeholders, including consumer and patient groups, professional medical associations, provider organizations, and industry.

As you move forward to implement this provision, we ask you to work quickly. The legislation  required  HHS to establish, by October l, 2011, reporting  procedures for applicable manufacturers to submit information to you, as well as procedures for making such information available to the public. Over one year later, these final regulations have not yet been released.

Many companies have already invested significant resources in preparing to comply with the Sunshine provision. The original statute required covered entities to begin collecting  payment information as of January 1, 2012, and to submit to HHS the required information on March 31, 2013.  However,  delays in establishing procedures for the submission  and public reporting of the required information  have made these deadlines unfeasible.

We request that final regulations be released no later than December of this year, so that manufacturers can begin implementing procedures in order to begin collecting  payment information.

This provision had bipartisan champions in Congress and has the support of both consumer groups and industry. Full implementation of this law will protect patients and help restore trust in our health care system.

Sincerely,                    

Thomas J. Schumacher
Vice President, Chief  Ethics  and Compliance Officer
Medtronic, Inc.

Allan  Coukell
Director, Medical Programs
The Pew Charitable Trusts 

Date added:
Nov 29, 2012

Related Resources

Test Your Knowledge of Antibiotics

Other Resource

Nearly nine in 10 Americans recognize that antibiotics are effective treatments for fighting bacterial infections like strep throat, but more than a third mistakenly believe the drugs are also appropriate treatments for viral infections such as the common cold. Test your antibiotics IQ and take the quiz.

More

''FDA Stakeholders Worry About Sequestration''

Media Coverage

"Representatives from the FDA and industry expressed serious concerns about the potential impact of sequestration Monday, saying it's not a good time to shortchange the agency when it's under so much pressure to help bring innovative new drugs to market."

More

''Report: State Prescription Monitoring Programs Falling Short''

Media Coverage
  • Sep 21, 2012

"Forty-nine states, including Maine, now operate a prescription monitoring program - or are putting one in place - to track the powerful pain medication dispensed by pharmacies. These databases have already helped in the fight to curtail diversion and abuse of prescribed opioids. But the way they operate - and how the data they collect gets used - varies widely from state to state."

More

A Healthy Dose of Bipartisanship

Opinion

Passed by Congress on June 26 and signed by President Obama on July 9, the FDA Safety and Innovation Act will increase inspections of foreign manufacturers that supply 80 percent of the ingredients in our pharmaceuticals, putting American companies on the same footing as their foreign competitors. In addition, it requires drug makers to hold their suppliers to high standards.

More

''FDA Probing Safety of Metal-on-Metal Hip Implants''

Media Coverage

"While thousands of Americans have benefited from hip replacements over the years, problems with metal-on-metal implants can lead to troubles requiring surgery to replace defective devices, experts say. Writing earlier this month in the New England Journal of Medicine, Pew's Joshua Rising and colleagues said that "there is now compelling evidence that these implants fail at a higher rate than hip prostheses made of other materials."

More